Ranitidine products are used to reduce the production of stomach acid in patients with conditions such as heartburn and stomach ulcers. They are available over-the-counter and on prescription.

Shares in GSK opened 1.9-percent lower in London following the results update. Over-the-counter treatment Zantac, known also by its non-commercial name ranitidine, was manufactured by several ...

Zantac was originated by GSK and launched by the company in the early 1980s, which sold it as a prescription and over-the-counter (OTC) product for indications like heartburn and acid indigestion ...

As the FDA’s investigation continued, they ultimately decided to issue an involuntary recall, pulling all prescription and ...

The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been ... early 1980s and sold it as a prescription and over-the-counter (OTC) product for indications like heartburn ...

According to the outlet, New York-based Pfizer sold over-the-counter ranitidine drugs also known as Zantac from 1998 through 2006. In 2019, a small laboratory in Connecticut found that ranitidine ...

The over-the-counter treatment, known also by its non-commercial name ranitidine, was manufactured by several rivals including the French group Sanofi and US drugmaker Pfizer before it was ...

as well as GSK — to pull Zantac off the market over mounting concerns that its active ingredient, ranitidine, could degrade into an organic chemical called NDMA, over time or when exposed to heat.

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen.

In 2020, US regulators halted the sale of Zantac over concerns that a key ingredient, ranitidine, had the potential to turn into a substance that may trigger cancer when exposed to heat.

(RTTNews) - GSK plc (GSK, GSK.L) announced that it has reached agreements with 10 plaintiff firms representing approximately 93% (around 80,000) of the Zantac ... steadily over the years to ...